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Sirtuins are critical regulators of many cellular processes, including insulin secretion, the cell cycle, and
apoptosis. Sirtuins are associated with a variety of age-associated diseases such as type II diabetes, obesity,
and Alzheimer’s disease. A thorough understanding of sirtuin chemical mechanisms will aid toward develop-
ing novel therapeutics that regulate metabolic disorders and combat associated diseases. In this review, we
discuss the unique deacetylase mechanism of sirtuins and how this information might be employed to
develop inhibitors and other molecular probes for therapeutic and basic research applications. We also cover
physiological regulation of sirtuin activity and how these modes of regulation may be exploited to manipulate
sirtuin activity in live cells. Development of molecular probes and drugs that specifically target sirtuins will
further understanding of sirtuin biology and potentially afford new treatments of several human diseases.
Introduction
Metabolic disregulation accounts for a growing number of
diseases including type II diabetes, metabolic syndrome, and
obesity. Understanding the regulatory mechanisms involved in
metabolism will allow development of drugs for treatment of
these diseases. Recent identification of sirtuins as novel regula-
tors of many metabolic processes makes sirtuins intriguing drug
targets. In addition to their involvement in age-related diseases
(Milne and Denu, 2008), sirtuins regulate many metabolic path-
ways such as insulin secretion and lipid mobilization. Sirtuins
are also implicated in control of metabolic protein regulators
such as AMP-activated protein kinase (AMPK) and LKB1 (Elliott
and Jirousek, 2008; Fulco et al., 2008; Lan et al., 2008).
The human sirtuin family is made up of seven members, Sirt1–
7, with each having distinct cellular targets and diverse cellular
localizations (Table 1). Most sirtuins possess NAD+-dependent
protein deacetylase activity. Sirt1 has been the most studied,
as it shares the highest homology with the founding member of
the Sir2 family from yeast. As many as 30 acetylated proteins
have been implicated as Sirt1 substrates, and the list will likely
continue to grow. Sirt1 is reported to regulate b cell insulin secre-
tion, mitochondrial biogenesis, and metabolic genes through
PGC1a, and to deacetylate Ku70 (reviewed in Westphal et al.,
2007). Sirt1 is localized to either the nucleus or cytoplasm de-
pending on tissue and cell type (Tanno et al., 2007). Sirt1 exhibits
variable expression that depends on tissue type, overnight fast-
ing, and caloric restriction (Chen et al., 2008; Cohen et al., 2004).
Sirt2 is localized mainly to the cytoplasm, where it is associated
with deacetylation of tubulin filaments, HOXA10, and FOXO (Bae
et al., 2004; Jing et al., 2007; North et al., 2003; Turdi et al., 2007;
Wang et al., 2007). Specific Sirt2 inhibitors discovered in vitro
were also shown to ameliorate a model system of Parkinson’s
disease, suggesting a potential link between specific sirtuin inhi-
bition and Parkinson’s treatment (Outeiro et al., 2007). Sirt3 is
genetically linked to lifespan in the elderly (Rose et al., 2003).
However, the function and localization of this enzyme is a matter
of some debate (Hallows et al., 2008). A number of reports indi-
cate that Sirt3, upon proteolytic cleavage in the mitochondria, is
an active protein deacetylase against a number of mitochondrial
matrix proteins (Schwer et al., 2002). In stark contrast, one report
suggested that full-length Sirt3 exhibits nuclear localization and
histone deacetylase activity (Scher et al., 2007). Recently, a re-
port comparing Sirt3/ and Sirt3+/+ mice provided compelling
evidence that endogenous Sirt3 is mitochondrial and is respon-
sible for the majority of protein deacetylation in this organelle
(Lombard et al., 2007). Sirt4 is localized to the mitochondria
but has exhibited no deacetylase activity to date. However,
Sirt4 is reported to ADP-ribosylate and inhibit glutamate dehy-
drogenase (Haigis et al., 2006). Similarly, Sirt5 is localized to
the mitochondria, but cellular targets remain unknown (Michi-
shita et al., 2005). Sirt5 was initially shown to possess weak
deacetylase activity and recently was suggested to effect cyto-
chrome c acetylation in vitro (Schlicker et al., 2008), although
the mouse knockout of Sirt5 does not affect the bulk acetylation
state of mitochondrial proteins (Lombard et al., 2007). Sirt6 is
localized to the nucleus, and the loss of Sirt6 leads to a shortened
lifespan and premature aging (Mostoslavsky et al., 2006). Sirt6
was initially reported to act as an ADP-ribosyltransferase (Liszt
et al., 2005) but histone deacetylase activity was recently dem-
onstrated, implicating Sirt6 in DNA damage repair, chromosome
stability, and modulation of telomeric DNA (Michishita et al.,
2008). Lastly, Sirt7 is associated with nucleoli, and is implicated
in activation of transcription by RNA polymerase I (Ford et al.,
2006).
The varied localization and activity of the human sirtuins place
them at the center of the many cellular pathways and functions
regulated by reversible acetylation. Yet because sirtuins control
a number of different pathways and exhibit diverse cellular local-
ization, there is a significant need for homolog-specific and tis-
sue-specific inhibitors, activators, andmolecular probes. Specif-
ically, Sirt1 is central to a number of metabolic processes such
as insulin secretion and AMPK regulation, and understanding
how Sirt1 regulates these cellular processes is critical. Specific
inhibitors, activators, and othermolecular probeswill be valuable
tools to understand sirtuin activity and regulation, and to develop
pharmaceuticals for treatment and prevention of age-related
diseases. Here we review current knowledge of sirtuin chemical
and regulatory mechanisms and how this knowledge might be
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standing of sirtuin biology.
Sir2 Chemical Mechanisms
Deacetylation Mechanism
Detailed comprehension of sirtuin-catalyzed chemical mecha-
nisms is vital to design drugs and other molecular probes that
target sirtuin enzymatic activity. Sirtuins exhibiting protein de-
acetylation activity catalyze NAD+-dependent deacetylation of
acetyl-lysine residues to form nicotinamide, deacetylated lysine,
and 20-O-acetyl-ADP-ribose (OAADPr) (Jackson and Denu,
2002; Sauve et al., 2001) (Figure 1). Sirtuins accomplish this re-
action through a bi-ter kinetic mechanism in which acetyl-lysine
binds prior to NAD+. Nicotinamide is the first product released,
followed by random release of deacetylated lysine and OAADPr
(Borra et al., 2004). Crystallographic evidence suggests that
bound acetyl-lysine forces the nicotinamide ring of NAD+ deep
within a conserved hydrophobic pocket (Avalos et al., 2004;
Zhao et al., 2004). In the first chemical step after both substrates
are bound, the acetyl oxygen undergoes nucleophilic attack of
the 10-carbon of the nicotinamide ribose to form the a-10-O-alky-
lamidate intermediate (Figure 1). Evidence supporting this inter-
mediate comes from several fronts. First, 18O-labeling studies
indicate that the acetyl oxygen is directly transferred to the 10-hy-
droxyl of OAADPr (Sauve et al., 2001; Smith and Denu, 2006).
Second, in a process known as nicotinamide exchange, sirtuins
catalyze incorporation of exogenously added [14C]nicotinamide
to form [14C]NAD+ in the presence of an acetyl-lysine substrate
and unlabeled NAD+ (Jackson et al., 2003; Landry et al., 2000;
Sauve and Schramm, 2003). Importantly, the acetyl-lysine sub-
strate is indispensable for nicotinamide-ribosyl bond cleavage
in both nicotinamide exchange and deacetylation reactions.
Substitution of 20-deoxy-20-fluoro-NAD+ for NAD+ arrested de-
acetylation but nicotinamide exchange was minimally affected,
indicating that acetyl-lysine attack proceeds at the 10-carbon
of the nicotinamide ribose (Jackson et al., 2003). Third,
Table 1. Summary of the Biology of the Human Sirtuins, Sirt1–7
Sirtuin
Disease
Implication Localization Substrates
Interacting
Partners Physiological Summary References
Sirt1 Metabolic,
neurological,
cardiovascular,
renal, cancer
Nuclear,
cytoplasmic
p53, Foxo1, Foxo4,
COUP-TF, CTIP2,
NFkB, p65, NCoR,
Histone H1, Histone H4,
Ku70, p300, BCL11A,
Tat, PGC1a, MEF2,
eNOS, AceCS1, E2F1,
Androgen receptor,
p73, Smad7, NBS1, Rb,
TLE1, IRS2, LXR,
SUV39H1, WRN,
TORC2
AROS, DBC1 Overexpression is
cardioprotective
against oxidative
stress and heart
aging.
Increases mitochondrial
biogenesis by deacetylation
and activation of PGC1a.
Overexpression shows
both a protective and
pro-aging role in neurons.
Murine knockout have
genomic instability and
severe developmental
defects.
Hsu et al., 2008;
Lagouge et al., 2006;
Li et al., 2008;
McBurney et al., 2003
Sirt2 Neurological,
metabolic,
cancer
Cytoplasmic Tubulin, Foxo,
Histone H4, 14-3-3
HOXA10,
HDAC6
In cellular and Drosophila
model of Parkinson’s
disease, inhibition of Sirt2
has protective effects.
Outeiro et al., 2007
Sirt3 Metabolic Mitochondrial AceCS2 Unknown Murine knockout displays
hyperacetylated
mitochondrial proteome.
Lombard et al., 2007
Sirt4 Metabolic Mitochondrial GDH, IDE,
ANT2, ANT3
Unknown Murine knockout has
increased GDH activity.
Haigis et al., 2006
Sirt5 Neurological Mitochondrial Unknown Unknown Murine serotonin receptor
knockout have increased
SIRT5 expression.
Sibille et al., 2007
Sirt6 Cancer Nuclear Histone H3 Unknown Murine knockout have
genomic instability
displaying premature
aging and predisposition
to cancer.
Mostoslavsky et al., 2006
Sirt7 Cardiovascular Nuclear RNA Pol I, p53 Unknown Murine knockout have
decreased lifespan with
inflammatory cardiac
hypertrophy.
Vakhrusheva et al., 2008
This table was adapted from Lavu et al., 2008.
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spectral as well as crystallographic detection of the correspond-
ing a-10-S-alkylamidate intermediate (Hawse et al., 2008; Smith
and Denu, 2007b).
For acetyl-lysine attack to form the O-alkylamidate intermedi-
ate, both SN1 and SN2 mechanisms have been proposed (Fig-
ure 1). A crystal structure of a yeast Sir2 homolog, Hst2, revealed
a ternary complex with an acetyl-lysine peptide and a nonhydro-
lyzable NAD+ analog (carba-NAD+) in a conformation that
precluded direct attack of the acetyl oxygen at the 10-carbon of
the nicotinamide ribose (Figure 1) (Zhao et al., 2004). This ob-
served conformation appeared to support an SN1 mechanism
in which a distinct oxacarbenium intermediate is formed prior to
acetyl oxygen attack. An alternative structure of a bacterial Sir2
homolog, Sir2Tm, revealed the first ternary complex structure
with native substrates acetyl-lysine andNAD+ bound in the active
site. A strikingly different NAD+ conformation was observed in
which the acetyl oxygen was placed 3.2 A˚ from the 10-carbon
on the a face of the nicotinamide ribose (Figure 1) (Hoff et al.,
2006). This NAD+ conformation satisfied the positioning
requirements for an SN2 mechanism. However, a more recent
structure of an acetyl-lysine peptide and the NAD+ analog,
DADMe-NAD+, bound to SirTm led the authors to propose a
nucleophilic displacement by electrophile migration mechanism
(a type of SN1 mechanism) in which nicotinamide and acetyl-
lysine remain stationary and an oxacarbenium intermediate
migrates from nicotinamide to the acetyl oxygen (Hawse et al.,
2008).
Recently, kinetic linear free-energy evidence consistent with
an SN2 mechanism was obtained utilizing a series of acetyl-
lysine analog peptides that varied greatly in the nucleophilicity
of the acetyl oxygen (Smith and Denu, 2007c). Acetyl-lysine pep-
tide displayed the fastest rate of nicotinamide formation (i.e.,
NAD+ cleavage) (6.7 s1), whereas the slowest analog trifluoroa-
cetyl-lysine peptide displayed a five order of magnitude slower
rate (1.1 3 105 s1). Utilizing Hst2 as a representative sirtuin,
the plot of log nicotinamide formation rate versus the Taft con-
stant, s* (Hansch and Leo, 1979), revealed a linear relationship
with a steep negative slope (r* = 1.9). Importantly, most of
the acetyl-lysine analog peptides exhibited binding constants
that were equal to or lower than that of acetyl-lysine peptide,
indicating the diminished rate of nicotinamide-ribosyl bond
cleavage was due to chemistry and not initial substrate binding.
These data were most consistent with an SN2 mechanism in
which the greater electron-withdrawing analogs exhibited de-
creased oxygen nucleophilicity and therefore slower nicotin-
amide formation rates, but other mechanisms could not be ruled
out. More recently, ab initio QM/MM calculations by Hu et al.
support an SN2 mechanism with a highly dissociative transition
state (P. Hu, S. Wang, and Y. Zhang, personal communication).
In the calculated transition state, the bond orders between the
acetyl oxygen and the 10-carbon, and the 10-carbon and nicotin-
amide were 0.10 and 0.14, indicating significant nucleophilic
participation of acetyl-lysine in nicotinamide-ribosyl bond cleav-
age. In addition, although formation of a distinct oxacarbenium
intermediate was not observed, the calculated transition state
Figure 1. The Proposed Mechanism of Sir2 Protein Deacetylases
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NAD+ cleavage mechanisms (Berti et al., 1997; Parikh and
Schramm, 2004; Rising and Schramm, 1997; Scheuring et al.,
1998; Scheuring and Schramm, 1997a, 1997b; Yang et al., 2007).
Whereas much of the evidence points to an SN2 mechanism
with a highly dissociative oxacarbenium transition state, determi-
nation of kinetic isotope effects for the Sir2 reaction would pro-
vide more definitive evidence whether or not acetyl-lysine
attack occurs in the same transition state as nicotinamide forma-
tion. The 15N isotope effect in N1 of nicotinamide as a function of
acetyl analog nucleophilicity would be particularly informative.
Other important isotope effects would be the 13C effect at the
10-carbonof thenicotinamide ribose and the 18Oeffect at theace-
tyl oxygen. With primary isotope effects for all of the atoms in-
volved directly in the reaction, it should be possible to definitively
establish the nature of the transition state for acetyl-lysine attack.
After O-alkylamidate formation, the 20-hydroxyl of the nicotin-
amide ribose is activated by an active-site histidine (His-135 in
Hst2) for attack of the O-alkylamidate carbon to form the 10,20-
cyclic intermediate (Sauve et al., 2006; Smith and Denu, 2006)
(Figure 1). To complete the reaction, several steps involving elim-
ination of deacetylated lysine followed by water addition result in
formation of 20-OAADPr. Following release from the sirtuin active
site,OAADPr undergoes nonenzymatic interconversion between
20-OAADPr and 30-OAADPr (Jackson and Denu, 2002; Sauve
et al., 2001). Although direct evidence for intermediates after
the O-alkylamidate remains elusive, several lines of evidence
are consistent with a two-step chemicalmechanism inwhich nic-
otinamide formation is followed by acetyl transfer. First, mutation
of the histidine general base to alanine hindered deacetylation,
whereas nicotinamide exchange was less affected (Jackson
et al., 2003), indicating nicotinamide-ribosyl bond cleavage
occurs in a distinct step prior to acetyl transfer. Second, rapid-
quenching kinetic analysis utilizing Hst2 revealed a rate of
nicotinamide formation of 8 s1, whereas acetyl transfer to the
20-hydroxyl occurred at a rate of 2 s1 (Borra et al., 2004). Product
release limits overall turnover at a rate (kcat) of 0.2 s
1 for Hst2
(Smith and Denu, 2006).
Comparison to Class I/II/IV Histone Deacetylases
The mechanism of Sir2 deacetylases (class III HDACs) stands in
stark contrast to that of class I/II/IV HDACs that utilize an active-
site zinc to direct hydrolysis of acetyl-lysine residues. The dis-
tinction between the two mechanisms is best exemplified by
comparison of the different roles played by the acetyl group. In
sirtuins, the acetyl oxygen is the nucleophile, whereas in class
I/II/IV HDACs the acetyl carbon is the electrophile. These mech-
anistic differences were recently highlighted by comparison of
the rates of deacylation of six acetyl-lysine analog peptides
(Smith and Denu, 2007a). It was hypothesized that greater elec-
tron-withdrawing acetyl analogs (e.g., trifluoroacetyl) would
increase the electrophilicity of the acetyl carbon and therefore
the deacylation rate by class I/II/IV deacetylases. Conversely,
these same electron-withdrawing analogs would decrease the
nucleophilicity of the acetyl oxygen and the deacylation rate by
sirtuins. Indeed, only a 7-fold difference in rate was observed
for an acetyl-lysine peptide between the sirtuin, Hst2, and the
class I HDAC, HDAC8, but a 300,000-fold faster rate for
HDAC8 compared to Hst2 for the corresponding trifluoroace-
tyl-lysine peptide. These differences were further manifested inChemistry & Biologthe divergent slopes of 1.57 for Hst2 and +0.79 for HDAC8 in
the Taft plots of the substituent electron-withdrawing nature
(s*) (Hansch and Leo, 1979) versus the log deacylation rate.
In the future, differences in chemical mechanism between
deacetylase classes might be exploited to develop selective
deacetylase substrates. For example, substitution of an acetyl-
lysine analog within existing fluorescent deacetylase substrates
may provide fluorescent activity readout for a particular subset of
HDACs. This approach has begun to be explored for class I and II
HDACs by the Jung and Schwienhorst labs utilizing propionyl-,
butyryl-, trifluoroacetyl-, and other acetyl-lysine analogs (Helt-
weg et al., 2004; Hildmann et al., 2006; Riester et al., 2004). Com-
bination of acetyl analog selectivity along with peptide sequence
selectivity could afford highly selective HDAC substrates. These
selective substrates could be useful to detect individual HDAC
activity within live cells. Toward this end, a homogeneous assay
suitable for high-throughput screening of class I/II/IV HDAC
activity in mammalian cells was reported in which an acetyl-
lysine fluorescent substrate was utilized (Ciossek et al., 2008).
In addition, direct measurement of class I/II/IV HDAC activity in
live cells via 19F-NMR has been reported with trifluoroacetyl-
lysine (Sankaranarayanapillai et al., 2006).
The majority of existing HDAC fluorescent substrates utilize
7-amino-4-methylcoumarin (AMC),whose fluorescence is partially
quenched through covalent attachment to the carboxyl of the
acetyl-lysine residue and the amino group of AMC. Deacetyla-
tion of this substrate liberates a trypsin protease site that cleaves
preferentially after deacetylated lysine to release fully fluorescent
AMC. Other fluorophores could be utilized in this assay. For
example, we have utilized a rhodamine 110-based fluorescent
substrate to measure sirtuin activity (Borra et al., 2005). Oxazine
dyes could also be used, as they have previously been employed
in similar protease substrates (Boonacker et al., 2003). Selective
substrates attached to diverse fluorescent dyes could allow
measurement of multiple HDAC activities simultaneously.
Acetyl-Lysine Binding
Utilizing a series of ten acetyl-lysine analog peptides, the
requirements for efficient acetyl-lysine binding were recently
examined (Smith and Denu, 2007a). The various acetyl analogs
varied in their nucleophile, electronic-withdrawing potential,
size, charge, and hydrophobicity. Among the acetyl-lysine ana-
log peptides, the binding constants (Kd) to Hst2 varied 75-fold,
from 3.3 to 260 mM. The Kd values yielded the strongest correla-
tion with the relative hydrophobicity of each acetyl analog, where
themost hydrophobic analogs (i.e., thioacetyl and trifluoroacetyl)
displayed the tightest binding. Modeling of the thioacetyl and
trifluoroacetyl analogs into the Hst2 active site provided rational-
ization for the observed hydrophobicity correlation. In particular,
the increased size and hydrophobicity of the trifluoromethyl
group of trifluoroacetyl-lysine filled a hydrophobic pocket de-
fined by Phe-67, Ile-117, and Ile-181, and the greater size and
hydrophobicity of the sulfur in thioacetyl-lysine filled a hydropho-
bic pocket defined by Phe-184 and Val-228. Notably, these
residues are conserved, suggesting that the trends with Hst2
will be applicable to other sirtuins.
The observed correlation of acetyl analog hydrophobicity and
binding has application in the development of fluorescence
polarization and other probes that bind within the acetyl-lysine
binding pocket. Tight-binding thioacetyl-, trifluoroacetyl-, andy 15, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1005
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application. These probes would be useful in screening for com-
pounds that specifically bind to the acetyl-lysine binding pocket
of sirtuins. Such a screenwould be particularly interesting for ho-
mologs that do not possess known deacetylase activity (e.g.,
Sirt4 and Sirt7) but may bind acetyl-lysine peptides. Recently,
a similar fluorescent polarization assay was developed through
attachment of a fluorescein label to SAHA, a general class I/II/
IV HDAC inhibitor FDA approved for the treatment of cutaneous
T cell lymphoma (Mazitschek et al., 2008).
Depropionylation and Debutyrylation
In addition to acetylation, there is growing evidence that the
3-amine of lysine residues can be propionylated or butyrylated.
Direct support for these modifications comes from two recent
proteomics studies by Zhao and coworkers that revealed that
histone lysine residues as well as the non-histone proteins
p53, p300, and CREB-binding protein (CBP) are propionylated
and butyrylated (Chen et al., 2007; Cheng et al., 2008). In addi-
tion, the authors found that p300 and CBP, which are known
acetyltransferases, were capable of catalyzing propionylation
and butyrylation. Garrity et al. (2007) have observed
propionylation and regulation of propionyl-CoA synthetase by
several acetyltransferases. Berndsen et al. demonstrated that
the acetyltransferase Esa1 can catalyze efficient propionylation
(Berndsen et al., 2007). Other evidence comes from the obser-
vation that rat liver extracts, as well as HDAC1, HDAC3, and
HDAC6, can efficiently hydrolyze propionyl-lysine but not
butyryl-lysine fluorescent substrates (Heltweg et al., 2004;
Riester et al., 2004).
We recently showed that Hst2, Sirt1, Sirt2, and Sirt3 catalyze
efficient depropionylation and debutyrylation (Smith and Denu,
2007a). Among these sirtuins, deacetylase activity was the great-
est, followed by depropionylase activity (29%–77%compared to
deacetylation) and then debutyrylase activity (2%–26% com-
pared to deacetylation). Hst2 exhibited the greatest depropiony-
lase activity but the slowest debutyrylase activity, suggesting
a more sterically restricted active site compared to Sirt1, Sirt2,
and Sirt3. Comparison of the NAD+ Km values with Sirt2 using
acetyl-, propionyl-, and butyryl-lysine peptides revealed a higher
Km value with propionyl- compared to acetyl-lysine peptide. This
higher Km value suggests that with propionyl-lysine peptide,
NAD+binding is adversely affectedwhereas nicotinamide-ribosyl
bond cleavage is not significantly affected. Conversely, butyryl-
lysine peptide displayed a lower Km value, suggesting that
nicotinamide-ribosyl bond cleavage is significantly perturbed
compared to acetyl- and propionyl-lysine substrates (Smith and
Denu, 2007a).
The extent and functions of propionylation and butyrylation
throughout the cell requires further investigation. Given the dif-
ferent acyl-group substrate selectivity among sirtuins, propiony-
lation and butyrylation could provide another level of regulation
at sites of known acetylation, either in antagonistic or agonistic
fashion. Additionally, it will be important to evaluate whether sir-
tuins that display little to no deacetylase activity (e.g., Sirt4–Sirt7)
may more effectively catalyze depropionylation/debutyrylation.
If these modifications prove to be a robust mode of regulation,
then it will be essential to explore the links between short-chain
fatty acyl-CoA metabolism and the enzymes that catalyze
reversible lysine acylation.1006 Chemistry & Biology 15, October 20, 2008 ª2008 Elsevier LtdSir2 ADP-Ribosylation Mechanism
Although protein deacetylation is thought to be the primary activ-
ity displayed by sirtuins, several reports have suggested that
some sirtuins (e.g., Sirt4 [Ahuja et al., 2007; Haigis et al., 2006]
and Sirt6 [Liszt et al., 2005]) possess ADP-ribosyltransferase
activity. Sirt6 was recently shown to also catalyze selective
deacetylation of lysine 9 of histone H3 (Michishita et al., 2008),
so it is reasonable to predict that yet unidentified deacetylase
substrates may exist for Sirt4. The ability of sirtuins to catalyze
multiple rounds of NAD+-dependent protein ADP-ribosylation
has not been demonstrated. Furthermore, the nature of the link-
age and site of modification remains unclear. Among deacety-
lases reported to harbor both activities, deacetylase activity is
three to five orders of magnitude greater than ADP-ribosylation
(Kowieski et al., 2008; Tanner et al., 2000). Kowieski et al. re-
cently determined the mechanism of ADP-ribosylation by
a Sir2 homolog from Trypanosoma brucei first characterized by
Garcı´a-Salcedo and coworkers to possess both deacetylase
and ADP-ribosyltransferase activity (Garcı´a-Salcedo et al.,
2003). Kowieski et al. suggested two distinct ADP-ribosylation
mechanisms, both of which require an acetyl-lysine substrate
(Kowieski et al., 2008). In one mechanism, acetyl-lysine reacts
with NAD+ to form the O-alkylamidate intermediate. The ability
of the O-alkylamidate intermediate to react with other exoge-
nous alcohols has been demonstrated (Smith and Denu, 2006),
indicating that amino acid side chains might intercept and react
with the O-alkylamidate resulting in ADP-ribosylation instead of
deacetylation. In a second ADP-ribosylation mechanism, the
acetyl-lysine substrate andNAD+ proceed through deacetylation
to formOAADPr, which then reacts nonenzymatically with a pro-
tein substrate resulting in ADP-ribosylation (Kowieski et al.,
2008).
Plasmodium falciparum Sir2 (PfSir2), which has reported
deacetylase and ADP-ribosyltransferase activity (Chakrabarty
et al., 2008; Merrick and Duraisingh, 2007), was recently shown
to hydrolyze NAD+ by two distinct mechanisms, one of which
did not require an acetyl-lysine substrate and was insensitive
to nicotinamide inhibition (French et al., 2008). Although it is un-
clear whether the acetyl-lysine-independent NAD-cleavage
pathway is directly linked to protein ADP-ribosylation, this
mechanism might reflect how some sirtuins catalyze direct
ADP-ribosyltransfer to protein nucleophiles in the absence of
an acetyl-lysine substrate and in a nicotinamide-insensitive
manner. Interestingly, Sirt4 is also suggested to display ADP-
ribosyltransferase activity in the absence of acetyl-lysine sub-
strates (Ahuja et al., 2007; Haigis et al., 2006). In this case, it
is possible that a protein side chain such as Asn or Gln could
replace acetyl-lysine to form a similar O-alkylamidate intermedi-
ate or that a direct-transfer ADP-ribosylation mechanism is
operative.
Acetyl-lysine analog peptides might serve as probes to distin-
guish between the above ADP-ribosylation mechanisms. In
particular, a homocitrulline peptide could be valuable due to its
ability to stall at the corresponding O-alkylamidate (or O-alkyli-
sourea) intermediate, not proceed to deacylation, and accept al-
ternative nucleophiles (Khan and Lewis, 2006; Smith and Denu,
2007a). For instance, substituting homocitrulline for acetyl-lysine
might increase ADP-ribosylation in a mechanism that reacts with
the O-alkylamidate (or O-alkylisourea) due to the increasedAll rights reserved
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might decrease ADP-ribosylation in a mechanism that requires
OAADPr.
In Vivo Modulation of Sirtuin Activity
Endogenous Protein Modulators of Sirtuin Activity. The variety
of important functions involving Sir2 deacetylases underscores
the need to understand the mechanisms that regulate their
physiological activity. To date, both a specific protein inhibitor
and activator of Sirt1 have been identified. Sirt1 was shown to
interact with and be activated by active regulator of Sirt1
(AROS) (Figure 2) (Kim et al., 2007). AROS is a 142 amino acid
nuclear localized protein that possessed no known function prior
to its identification as a Sirt1 binding partner. AROS interacted
with Sirt1 both in vitro and in cell extract, and the expression pro-
files of AROS and Sirt1 were similar. Interestingly, activation of
Sirt1 by AROS appeared greater in cellular studies compared
to in vitro experiments. This finding could indicate that AROS
works with another protein factor in vivo or acts as a derepressor
by displacing other inhibitory factors such as DBC1 (see below).
Further work is needed to determine the mechanism of AROS-
mediated Sirt1 activation. In particular, does AROS induce a
conformational change in Sirt1 or does AROS binding affect
other interacting proteins that regulate Sirt1 activity? Identifica-
tion of tissues and protein targets that are affected by the
AROS/Sirt1 interaction will be necessary to understand its phys-
iological relevance. Discovery of compounds that disrupt AROS
binding to Sirt1 would be valuable. Utilization of these com-
pounds will allow researchers to determine the effect of AROS
activation on Sirt1-dependent processes, as well as what poten-
tial therapeutic benefits the AROS/Sirt1 interaction may hold.
Recent studies revealed that human deleted in breast cancer 1
(DBC1) is a specific Sirt1 inhibitor (Kim et al., 2008; Zhao et al.,
2008) (Figure 2). DBC1 was previously identified from a region
that is homozygously deleted in breast cancer (Hamaguchi
et al., 2002). DBC1 was shown to bind and inhibit
Sirt1-catalyzed deacetylation of p53 in vivo. Through siRNA
knockdown of DBC1, Sirt1 was activated and the inhibition of
apoptosis by p53 was decreased. In vitro assays revealed that
inhibition occurred through binding of a leucine-zipper-like motif
within DBC1 to the catalytic domain of Sirt1. Curiously, DBC1
also contains a catalytically inactive version of a Nudix hydrolase
(MutT) domain (Anantharaman and Aravind, 2008). Homologs of
the Nudix domain were shown to bind NAD+-like molecules and
the product of sirtuin deacetylation, OAADPr (Grubisha et al.,
2006). Anantharaman and Aravind proposed that OAADPr bind-
ing to DBC1may facilitate Sirt1 inhibition and/or binding of DBC1
to Sirt1 (Anantharaman and Aravind, 2008). Understanding how
NAD+ and OAADPr levels regulate DBC1 binding to Sirt1 injects
a fascinating possibility for allosteric regulation of Sirt1 activity.
Another interesting aspect of regulation of Sirt1 may be the inter-
play between AROS and DBC1. In particular, are the binding of
AROS and DBC1 to Sirt1 mutually exclusive, and/or dependent
upon metabolites? In addition, the potential relationship be-
tween DBC1, Sirt1, and resveratrol is intriguing. The observed
in vivo Sirt1 activation by resveratrol has proved difficult to repro-
duce in vitro (Borra et al., 2005; Kaeberlein et al., 2005). This is
Figure 2. Known Posttranslational Modifications, Interacting Proteins, and Binding Sites of the Human Sir2 Homologs Sirt1, Sirt2, and Sirt3Chemistry & Biology 15, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1007
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ing an inhibitory factor such as DBC1. Screening for novel Sirt1
activators through disruption of DBC1 binding to Sirt1 could
afford compounds that treat age-related diseases.
Posttranslational Modification of Sirtuins
Phosphorylation of Sirt2. Sirt2 is phosphorylated at both Ser-368
andSer-331 (Figure 2) (North and Verdin, 2007; Pandithage et al.,
2008). Dryden et al. showed that Sirt2 protein abundance and
phosphorylation decreased when the phosphatase CDC14B
was overexpressed in cell culture, and that phosphorylation
might inhibit Sirt2 degradation through the 26S proteasome (Dry-
den et al., 2003). However, the site of phosphorylation was not
identified. In addition, Sirt2 phosphorylation at Ser-368 is in-
volved in mitotic regulation from G2 to M phase. The kinase
CDK1 and the phosphatases CDC14A and CDC14B reversibly
regulated Sirt2 and therefore control of the cell cycle from G2
to M phase (North and Verdin, 2007). Interestingly, phosphoryla-
tion at Ser-331 inhibited the Sirt2 deacetylase activity, but the
mechanism of inhibition is unknown (Pandithage et al., 2008).
Ser-331 phosphorylation and inactivation was shown to interfere
with cell adhesion and cell migration.
Phosphorylation is a newly discovered and interesting layer of
sirtuin regulation, but determination of the role and extent of sir-
tuin phosphorylation requires further investigation. Using similar
unbiased techniques as that used by Pandithage et al. (2008),
one could elucidate other sirtuin phosphorylation sites. Further-
more, the use of specific kinase and phosphatase inhibitors in
cellular and tissue studies will help elucidate the function of
each sirtuin phosphorylation site.
Sumoylation of Sirt1. Sirt1 is modified at Lys-734 by the addition
of a sumo group, which activates Sirt1 deacetylase activity
(Yang et al., 2007) (Figure 2). An increase in Sirt1 sumoylation
by reduction of the sumoylase SENP1 increased Sirt1 deacety-
lation activity. It was hypothesized that stress-inducing agents
such as UV light and peroxide treatment counteract the anti-
apoptotic activity of Sirt1 by recruiting SENP1 to Sirt1. SENP1
recruitment resulted in desumoylation and repression of Sirt1
deacetylase activity and consequent acetylation and activation
of apoptotic proteins. Further studies are needed to determine
how sumoylation affects other Sirt1 posttranslational modifica-
tions and interacting partners. Do sumoylation and AROS work
together to activate Sirt1, are they tissue specific, or are they
mutually exclusive? Can Sirt1 be sumoylated but inhibited by
DBC1 or does sumoylation prevent DBC1 inhibition? What are
the cellular cues that inhibit Sirt1 by DBC1 or activate Sirt1 by
sumoylation and/or AROS? Critical toward answering these
questions is the ability to obtain stoichiometrically sumoylated
Sirt1. Chemical sumoylation could be accomplished through
expressed protein ligation similar to the synthesis of stoichio-
metrically ubiquitinylated histone H2B reported by the Muir lab
(McGinty et al., 2008).
Proteolytic Cleavage of Sirtuins. Sir2a, the mouse Sirt1 homolog,
is cleaved by caspases during apoptosis (Ohsawa and Miura,
2006). Caspase activation during apoptosis controls cleavage
of proteins during cellular degradation. In addition, Sirt1 has
been linked to increased longevity through p53 (Lain et al.,
2008). Therefore, Sir2a proteolytic cleavage during apoptosis
was suggested to inhibit the deacetylase activity and thus the
protective effects of Sir2a. Further work is needed to determine1008 Chemistry & Biology 15, October 20, 2008 ª2008 Elsevier Ltdwhether Sir2a proteolytic cleavage is consistent with human
Sirt1 regulation, andwhether caspase-dependent Sirt1 cleavage
is required for apoptosis.
Sirt3 was shown to undergo proteolytic cleavage upon trans-
location into the mitochondria. In contrast to caspase-mediated
cleavage of Sir2a, cleavage of the Sirt3 mitochondrial localiza-
tion sequence activates deacetylase activity. Full-length Sirt3
is proposed to be inactive until it is translocated to and proteolyt-
ically processed within the mitochondria to the active 28 kDa
protein (Figure 2) (Schwer et al., 2002). The role of full-length
inactivity is presumably to protect the cell from deacetylation
until Sirt3 enters the mitochondria, because spurious deacetyla-
tion could cause misregulation of the multitude of cytoplasmic
and nuclear processes potentially controlled by reversible acet-
ylation. Similar to Sirt3, Sirt4 is proteolytically processed to
remove the N-terminal 28 amino acids upon translocation to
the mitochondria, although it is unclear what role this cleavage
plays beyond mitochondrial localization (Ahuja et al., 2007).
NAD+ Salvage Pathway
The role of the NAD+ salvage pathway in physiological regulation
of sirtuin activity was recently reviewed (Denu, 2007; Grubisha
et al., 2005). Yet, in the last year, several studies reiterated the
importance of NAD+ metabolism in sirtuin regulation. Yang
et al. suggested that increased NAD+ levels in combination with
genotoxic stress activate sirtuins resulting in cellular protective
effects (Yang et al., 2007). Increased nicotinamide phosphoribo-
syltransferase (NAMPT) levels in fasted rats were effective for
protection from apoptosis in the presence of Sirt3 and Sirt4.
NAMPT is transcriptionally regulated by AMPK, which in turn
can regulate NAD+ levels and thus deacetylase activity (Fulco
et al., 2008). Upon AMPK activation by reduced glucose, NAMPT
is transcriptionally upregulated, which increasesNAD+ levels and
subsequently Sirt1 deacetylase activity. This glucose-mediated
signaling cascade was inhibited in mice that were heterozygous
for the SIRT1 gene, demonstrating that Sirt1 is integral to the
cells’ ability to sense reduced glucose andNAD+ availability. Fur-
ther knowledge ofNAD+metabolismand the role of sirtuins could
have great impact on understanding metabolic syndrome and
other metabolic dysfunctions.
Small-Molecule Modulation of Sirtuin Activity
Small-Molecule Sirtuin Activators and Inhibitors. The mecha-
nism of action and therapeutic potential of small-molecule sirtuin
inhibitors and activators has been recently reviewed (Milne and
Denu, 2008). As reviewed, the first putative sirtuin activators,
specific to Sirt1, were polyphenols from plant metabolites (e.g.,
resveratrol). However, the in vivo Sirt1 activation by resveratrol
has been difficult to reproduce in vitro (Borra et al., 2005; Kae-
berlein et al., 2005), suggesting that resveratrol may activate
sirtuins indirectly. Regardless, the identification of these sir-
tuin-specific activators has helped further understanding of
sirtuin biology. More recently, Milne et al. have shown that
Sirt1-specific activators, structurally unrelated to resveratrol,
could provide novel treatments of type II diabetes (Milne et al.,
2007). The identification and characterizing of specific sirtuin
activators will be valuable to uncover the basic regulatory role
of sirtuins in the cell and may be used as potential therapeutics
to treat various diseases in which sirtuins are implicated.
As sirtuin inhibitors have been recently reviewed (Milne and
Denu, 2008; Neugebauer et al., 2008), only a few recent studiesAll rights reserved
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eosin, a known inhibitor of both protein arginine and histone
lysine methyltransferases, that also inhibited histone acetyl-
transferases and Sirt1/Sirt2 with similar potency in vitro (Mai
et al., 2008). When tested on a human leukemia cell line, these
inhibitors induced dose-dependent cytodifferentiation and high
apoptosis levels, whereas single-target inhibitors (e.g., sirtinol
and curcumin) were ineffective. This study suggested that
promiscuous inhibitors of enzymes that control epigenetic mod-
ification might be more effective in some instances than their
selective counterparts. However, as only arginine methylation
was monitored in cells, further work is needed to determine
whether the observed effect is due to promiscuous enzyme inhi-
bition. Lain et al. carried out a cell-based screen to discover
small-molecule p53 activators that decrease tumor growth
(Lain et al., 2008). Their hit compounds, tenovin-1 and a more
water-soluble analog, tenovin-6, were shown to inhibit Sirt1
and Sirt2 via yeast genetic screening, biochemical assays, and
target validation studies. These tenovins were active on mam-
malian cells at low micromolar concentrations and decreased
tumor growth in vivo as single agents. Catoire et al. reported
evidence that sirtuin inhibition might provide a basis for the treat-
ment of oculopharyngeal muscular dystrophy, which is caused
by polyalanine expansion in the nuclear protein PABPN1 (Catoire
et al., 2008). In particular, the authors showed that survival of
mammalian cells expressing mutant PABPN1 was promoted
by the sirtuin inhibitor, sirtinol, and decreased by the putative
Sirt1 activator, resveratrol. Kiviranta et al. described new Sirt2
inhibitors based on the N-(3-phenylpropenoyl)-glycine trypta-
mide backbone and analyzed their binding modes through vari-
ous computational methods (Kiviranta et al., 2008). Huhtiniemi
et al. reported oxadiazole-carbonylaminothioureas that inhibited
Sirt1 and Sirt2 with potency in the low micromolar range (Huhti-
niemi et al., 2008). Chakrabarty et al. identified surfactin, a cyclic
lipopeptide, as a novel inhibitor of Plasmodium falciparum Sir2
(PfSir2) (Chakrabarty et al., 2008). Kinetic analysis revealed
that surfactin competes for NAD+ binding but not acetyl-lysine
substrate binding, with Ki values of 8 mM and a Kd value of
20 mM. Interestingly, surfactin was also shown to inhibit growth
of malarial parasites in culture with an IC50 value of 9 mM,
but whether this effect is due to PfSir2 inhibition remains to be
seen.
Mechanism-Based Sirtuin Inhibitors. Existing small-molecule
sirtuin inhibitors rely on competitive binding with either acetyl-
lysine or NAD+ substrates. Inhibitors that take advantage of
the unique sirtuin catalytic mechanism have been less exploited.
Inhibition of Sirt1 by a thioacetyl-lysine peptide was first de-
scribed by Fatkins et al. (2006). Subsequently, it was demon-
strated that a similar thioacetyl-lysine peptide exhibited potent
mechanism-based inhibition of Sirt1, Sirt2, Sirt3, and Hst2
(Smith and Denu, 2007b). For Hst2, this thioacetyl-lysine peptide
yielded a Kis value of 17 nM, 280-fold lower than its Kd value of
4.7 mM. This potent inhibition resulted from fast nicotinamide
cleavage from NAD+ (4.5 s1) but slow turnover (0.0024 s1) to
products 10-SH-OAADPr and deacetylated peptide, indicating
an inhibitory mechanism in which thioacetyl-lysine peptide stalls
at a catalytic intermediate after nicotinamide cleavage (Fig-
ure 3A). Solvent isotope effects, mass spectral analysis, density
functional calculations, and general base mutational analysisChemistry & Biologsuggested a stalled a-10-S-alkylamidate intermediate. More
recently, Hawse et al. reported crystallographic evidence in
which this S-alkylamidate was directly observed bound to
Sir2Tm (Hawse et al., 2008). The discovery of thioacetyl-lysine
mechanism-based inhibitors allows for development of several
unique probes to study sirtuin biology. Examples of these
probes include novel sirtuin mechanism-based inhibitors, selec-
tive inhibitors, selective spectrophotometric substrates, and
activity-based probes.
For further development of mechanism-based inhibitors,
alternate sirtuin substrates that display more rapid nicotinamide
formation or slower turnover (or formation of a dead-end com-
plex) would exhibit greater sirtuin inhibition compared to thioa-
cetyl-lysine. Selective sirtuin inhibitors might be developed
through substitution of thioacetyl-lysine for acetyl-lysine into
sirtuin-specific substrates. Fatkins and Zheng utilized the pep-
tide sequence of a-tubulin, a selective Sirt2 substrate (North
et al., 2003), to discover a thioacetyl-lysine-based Sirt2 inhibitor
that was 10- and 39-fold selective over Sirt1 and Sirt3, respec-
tively (Fatkins and Zheng, 2008b). To move from peptide-based
to small-molecule-based thioacetyl-lysine inhibitors, a substrate
activity screening approach pioneered by the Ellman lab could
be utilized (Patterson et al., 2007). In such an approach, a library
of acetyl-lysine-based fluorescent substrates would be
screened, and then the best substrates would be converted to
inhibitors by replacement of acetyl-lysine with thioacetyl-lysine.
A similar approach has been utilized to discover HDAC6-selec-
tive inhibitors through preparation of thiolate analogs of
selected small-molecule fluorescent substrates (Suzuki et al.,
2006).
Selective sirtuin substrates for a spectrophotometric assay
could be developed if a sirtuin does not display a diminished
rate of dethioacetylation compared to deacetylation. The 10-thiol
of the 10-SH-OAADPr product could be detected with thiol-
reactive reagents (e.g., Ellman’s reagent) similar to an existing
HDAC8 assay that detects thioacetate formed from dethioacety-
lation (Fatkins and Zheng, 2008a). To develop activity-based
probes, addition of a tag (e.g., fluorophore or biotin) and a photo-
labeling group (e.g., benzophenone) to a thioacetyl-lysine pep-
tide might allow simultaneous detection of deacetylase activity
displayed by multiple sirtuins within cell extracts (Figures 3B
and 3C). Alternatively, the photolabeling group could covalently
label sirtuin-associated proteins, providing facile identification of
sirtuin complexes. A similar approach has been reported by the
Cravatt lab for class I and II HDACs through modification of the
general HDAC inhibitor, SAHA, to incorporate a benzophenone
photolabeling group and an alkyne tag (Salisbury and Cravatt,
2007, 2008). The authors found that both class I and II HDACs
as well as other HDAC-associated proteins were labeled using
this method. The modularity of the thioacetyl-lysine peptide
inhibitor is well suited for these above applications because of
the facile synthesis, control of sequence, and ease of peptide
derivatization in solid-phase peptide synthesis.
Conclusions and Future Directions
Recent research has furthered our understanding of the
chemical and regulatory mechanisms catalyzed by sirtuins, but
creative application of chemical biology will be necessary to de-
velopmolecular probes and therapeutic agents that target sirtuiny 15, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1009
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HDAC classes will be particularly difficult. However, understand-
ing mechanistic differences between HDAC classes, especially
in regard to acetyl binding/reactivity and the unique use of
NAD+ by sirtuins, will prove fruitful. In this respect, mechanism-
based sirtuin inhibitors such as thioacetyl-lysine and other
acetyl-lysine analogs are particularly promising. In addition, tar-
geting in vivo modulators of sirtuin activity rather than sirtuins
themselves may provide higher selectivity. Future development
of specific sirtuin inhibitors, activators, and molecular probes
will further understanding of sirtuin biology and treatments of
age-associated diseases.
Figure 3. An Example Application of the Mechanism-Based Inhibition Displayed by Thioacetyl-Lysine Peptides
(A) Proposed inhibition mechanism of thioacetyl-lysine peptides.
(B) Modular design of a sirtuin activity-based photolabeling probe.
(C) Example experiment utilizing a sirtuin activity-based photolabeling probe to identify disease-specific sirtuin activities.
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